Applied Therapeutics/APLT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Applied Therapeutics

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.

Ticker

APLT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Shoshana Shendelman

Employees

26

Headquarters

New york, United States

APLT Metrics

BasicAdvanced
$489M
Market cap
-
P/E ratio
-$1.91
EPS
1.89
Beta
-
Dividend rate
$489M
1.88947
$9.39
$1.18
906K
1.799
-213.60%
-612.33%
-604.11%
7.266
7.268
-104.47%
-4.58%

What the Analysts think about APLT

Analyst Ratings

Majority rating from 5 analysts.
Buy

APLT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-83,900.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$100K
-98.99%
Net income
-$84M
-29.91%
Profit margin
-83,900.00%
6,839.10%

APLT Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 320.06%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.37
-$0.47
-$0.34
-$0.67
-
Expected
-$0.27
-$0.26
-$0.23
-$0.16
-$0.18
Surprise
39.62%
81.23%
49.12%
320.06%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Applied Therapeutics stock?

Applied Therapeutics (APLT) has a market cap of $489M as of June 15, 2024.

What is the P/E ratio for Applied Therapeutics stock?

The price to earnings (P/E) ratio for Applied Therapeutics (APLT) stock is 0 as of June 15, 2024.

Does Applied Therapeutics stock pay dividends?

No, Applied Therapeutics (APLT) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next Applied Therapeutics dividend payment date?

Applied Therapeutics (APLT) stock does not pay dividends to its shareholders.

What is the beta indicator for Applied Therapeutics?

Applied Therapeutics (APLT) has a beta rating of 1.89. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Applied Therapeutics stock price target?

The target price for Applied Therapeutics (APLT) stock is $11.4, which is NaN% below the current price of $. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Applied Therapeutics stock

Buy or sell Applied Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing